GlassScriptPhysician profile
Keith D Rigsby
NPI 1952359622
$2,802.64
in general payments reported to CMS, 2019-2025
36 companies · $634 in 2025
The $634 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $346 · 2020: $169 · 2021: $294 · 2022: $335 · 2023: $603 · 2024: $422 · 2025: $634.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,659.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,658.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $381.89 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $252.24 | 2019-2024 | |
| Abbvie INC. | $222.18 | 2021-2025 | Viberzi, Linzess |
| Dexcom, INC. | $193.02 | 2021-2025 | Dexcom G6 Transmitter |
| Edwards Lifesciences Corporation | $170.53 | 2025 | Sapien 3 Ultra Resilia |
| Corcept Therapeutics | $163.61 | 2023-2025 | Korlym |
| Corium, LLC | $127.91 | 2023-2025 | Azstarys |
| Gilead Sciences, INC. | $115.85 | 2019 | |
| Sage Therapeutics, LLC | $102.80 | 2022 | |
| Greenwich Biosciences, INC. | $82.55 | 2019 | |
| Janssen Pharmaceuticals, INC | $80.05 | 2020-2021 | |
| Lilly USA, LLC | $67.95 | 2023-2025 | Jardiance, Emgality, Mounjaro |
| Analog Devices INC. | $67.76 | 2024-2025 | Sensinel Cpm Wearable |
| Sanofi-Aventis U.S. LLC | $64.91 | 2020-2022 | |
| Otsuka America Pharmaceutical, INC. | $62.93 | 2022-2024 | Rexulti |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bolton Medical INC | $61.50 | 2025 | Treo Abdominal Stent-Graft System |
| Tris Pharma INC | $57.41 | 2023-2024 | Dyanavel Xr |
| Novartis Pharmaceuticals Corporation | $51.11 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $46.76 | 2023 | Austedo Xr |
| Insulet Corporation | $43.72 | 2023 | Omnipod |
| Amgen INC. | $42.86 | 2019-2025 | Otezla, Repatha, Krystexxa |
| Amarin Pharma, INC. | $39.31 | 2019 | |
| Medtronic, INC. | $38.81 | 2021-2025 | Vanta Adaptivestim |
| Alkermes, INC. | $34.14 | 2023 | Aristada, Lybalvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.64 | 2022 | |
| Allergan, INC. | $28.71 | 2020 | |
| Axsome Therapeutics, INC. | $23.64 | 2025 | Auvelity |
| Ironwood Pharmaceuticals, INC | $19.36 | 2019 | |
| Ironshore Pharmaceuticals INC. | $17.08 | 2024 | |
| Shield Therapeutics INC | $16.67 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.52 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $16.28 | 2024 | Farxiga |
| Xeris Pharmaceuticals, INC. | $15.89 | 2021 | |
| Cequr Corporation | $15.52 | 2024 | Cequr Simplicity |
| Noven Therapeutics, LLC | $14.97 | 2024 | Secuado |
| Opko Pharmaceuticals, LLC | $12.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Rigsby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.